Diferencia entre revisiones de «EBQ:CRASH-2 Trial»
Sin resumen de edición |
Sin resumen de edición |
||
| Línea 17: | Línea 17: | ||
==Clinical Question== | ==Clinical Question== | ||
'''Does administration of tranexamic acid reduce the risk of death if administered early in severe trauma?''' | |||
==Conclusion== | ==Conclusion== | ||
'''Tranexamic acid improves survival when administered in less than 3 hrs after injury in patients with significant hemorrhage.''' | |||
==Major Points== | ==Major Points== | ||
Revisión del 03:02 5 ene 2014
incomplete Journal Club Article
Shakur H, et al. "Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage". The Lancet. 2010. 376(9734):23-32.
PubMed Full text PDF
PubMed Full text PDF
Clinical Question
Does administration of tranexamic acid reduce the risk of death if administered early in severe trauma?
Conclusion
Tranexamic acid improves survival when administered in less than 3 hrs after injury in patients with significant hemorrhage.